Tag Archives: ACI

Business, Finance, Occupation & Industry

24/7 Wall St. Closing Bell — March 18, 2013: Markets Slide on Cyprus Woes (KMB, VZ, RGLD, ACI, HPQ, SYNM, CLSN, HSOL, HAST, KIOR, FF, SBLK, FDS, CTAS, GLUU, JCP, NOK, BBRY)

Leave a comment

By 24/7 Wall St.

Bull and Bear figures

Filed under:

U.S. equity markets opened lower this morning following a weekend of confusion over the proposed solution to the banking problem in Cyprus. It’s not that Cyprus claims a particularly large banking system, but the proposed haircut for their depositors makes depositors everywhere wary (more coverage here). The Cypriot banking mess chilled markets in Asia and Europe today as well. There was little data released today, but the eurozone trade deficit came in higher than forecast and in China, house prices rose 2.1% month-over-month. In the U.S. the National Association of Home Builders index fell again in March, the second straight month of decline (more coverage here). U.S. financial stocks performed poorly today, while tech stocks posted a gain as speculation abounded that Apple Inc. (NASDAQ: AAPL) would seriously boost its dividend.

The U.S. dollar index rose 0.48% today, now at 82.654. The GSCI commodity index is up 0.4% at 652.50, with commodities prices mostly lower today on the stronger dollar. WTI crude oil closed up 0.3% today, at $93.74 a barrel. Brent crude trades down 0.2% at $109.57 a barrel. Natural gas is down 0.1% today at about $3.87 per million BTUs. Gold settled up 0.8% today at $1,604.60 an ounce, its first close above $1,600 this month.

The unofficial closing bells put the DJIA down about 62 points to 14,452.06 (-0.43%), the NASDAQ fell more than 11 points (-0.35%) to 3,237.59, and the S&P 500 fell -0.55% or nearly 9 points to 1,552.10.

There were a several analyst upgrades and downgrades today, including Kimberly-Clark Corp. (NYSE: KMB) cut to ‘sell’ at Goldman Sachs; Verizon Communications Inc. (NYSE: VZ) raised to ‘buy’ at Citigroup (more coverage here); Royal Gold Inc. (NASDAQ: RGLD) started as ‘buy’ at BB&T; Arch Coal Inc. (NYSE: ACI) raised to ‘neutral’ at Nomura; and Hewlett-Packard Co. (NYSE: HPQ) raised to ‘overweight’ at Morgan Stanley.

Earnings reports since markets closed last Friday resulted in several price moves today, including these: Syntroleum Corp. (NASDAQ: SYNM) is down 12.3% at $0.40; Celsion Corp. (NASDAQ: CLSN) is up 1.9% at $1.08; Hanwha Solarone Co. Ltd. (NASDAQ: HSOL) is up 5.7% at $0.93; Hastings Entertainment Inc. (NASDAQ: HAST) is down 4.4% at $2.17; and Kior Inc. (NASDAQ: KIOR) is down 0.9% at $5.76.

Before markets open tomorrow morning we are scheduled to hear from FutureFuel Corp. (NYSE: FF), Star Bulk Carriers Corp. (NASDAQ: SBLK), FactSet Research Systems Inc. (NYSE: FDS), and Cintas Corp. (NASDAQ: CTAS).

Some standouts among heavily traded stocks today include:

Glu Mobile Inc. (NASDAQ: GLUU) is up 11.1% at $3.71. The mobile games developer has been upgraded by several analysts.

J.C. Penney Co. Inc. (NYSE: JCP) is up 6.6% at $16.50. The beleaguered retailer gets a boost today from an analyst’s plan to convert some of the company’s stores to a REIT.

Nokia Corp. (NYSE: NOK) is down 2.3% at $3.35. The handset maker is declining as the U.S. release of the new smartphone from BlackBerry (NASDAQ: BBRY) approaches later this week..

Stay tuned for Tuesday. The Federal Open Market Committee (FOMC) begins its …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Dendreon Announces Securities Class Action Settlement

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Dendreon Announces Securities Class Action Settlement

SEATTLE–(BUSINESS WIRE)– Dendreon Corporation (NAS: DNDN) today announced that it has reached an agreement in principle to settle the securities class action litigation pending against it in the United States District Court for the Western District of Washington. Upon final approval, the settlement will resolve the claims asserted against all defendants in the previously disclosed putative securities class action. The lawsuit is currently pending against the Company and three current and former executive officers.

In the lawsuit, captioned In re Dendreon Corporation Class Action Litigation, Master Docket No. C 11-1291 JLR., an investor, purporting to represent a class consisting of persons who purchased Dendreon common stock between April 29, 2010 and August 3, 2011, sought unspecified damages from Dendreon and three current and former officers of the Company for allegedly false or misleading statements concerning the Company, its finances, business operations and prospects with a focus on the market launch of PROVENGE and related forecasts concerning physician adoption, and revenue from sales of PROVENGE.

The terms agreed upon by the parties contemplates a settlement payment of $40 million, $38 million of which will be funded by Dendreon’s insurers. Dendreon and the individual defendants continue to deny that any statements they made were false or misleading.

“We are pleased to put this matter behind us,” said Christine Mikail, Executive Vice President, Corporate Development, General Counsel and Secretary of Dendreon. “Upon final approval of this settlement, Dendreon will have eliminated the potential distraction from ongoing class action litigation that began in 2011.”

The terms of the settlement must be formally documented and are subject to approval by the District Court following notice to all class members. While the Company expects the settlement will receive the needed approval, the process normally takes several months.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ADA-ES Awarded Contracts for 10 Activated Carbon Injection Systems from Three Utilities

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ADA-ES Awarded Contracts for 10 Activated Carbon Injection Systems from Three Utilities

Awards highlight ADA’s continued traction in the emission control equipment market

Company to present at the 25th Annual ROTH Conference on March 18th

HIGHLANDS RANCH, Colo.–(BUSINESS WIRE)– ADA-ES, Inc. (NAS: ADES) (“ADA“) today announced that it has received awards from three utilities to supply ten Activated Carbon Injection (ACI) systems. Work on the contracts, which collectively are valued at more than $7 million, will begin immediately with deliveries in the fourth quarter of 2013 and in 2014.

The contracts are the result of the recent EPA Mercury and Air Toxics Standard (MATS), which requires coal-fired power plants to reduce emissions of mercury and sulfuric, hydrochloric and other acid gases by April 2015. ADA believes that MATS and other emission control regulations could generate a total market in excess of $1 billion for ACI and Dry Sorbent Injection (DSI) systems, and the Company expects to maintain a combined market share of about 35%. The enactment of MATS has recently created a significant increase in ACI and DSI procurement activities, and ADA has been active in its response to this market. With these new contracts ADA has received awards for DSI and ACI systems with a potential total value of over $50 million. In addition to these awards, ADA has active bids totaling over $125 million for ACI systems and over $160 million for DSI systems.

Dr. Michael Durham, President and CEO of ADA, stated, “We are very pleased to be awarded these projects by our customers and proud to provide them with solutions to ensure compliance with the new federal rules. The market for equipment to meet the federal MATS rules continues to accelerate and we expect that additional contracts for DSI and ACI systems will be awarded soon.”

The 25th Annual ROTH Conference

ADA will be presenting at the 25th Annual ROTH Conference at 9AM PDT on March 18th. The presentation will not be webcast; however a copy of the slides to be used at this event will be available via the Investor Information section of ADA‘s web site, www.adaes.com, on or before March 18, 2013, and will also be filed on Form …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

Dendreon Announces Webcast Presentation at ROTH Conference

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

Dendreon Announces Webcast Presentation at ROTH Conference

SEATTLE–(BUSINESS WIRE)– March 12, 2013—Dendreon Corporation (NAS: DNDN) today announced that management will present at the 25th Annual ROTH Conference in Laguna Niguel, California, on March 18, 2013, at 11:00 a.m. PT.

The presentation will be webcast live and available for replay from Dendreon’s website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.

Dendreon Corporation
Corporate Communications
Lindsay Rocco, 862-596-1304
media@dendreon.com
or
Dendreon Corporation
Investor Relations
Nicole Soley, 206-455-2384
InvestorRelations@dendreon.com

KEYWORDS:   United States  North America  California  Washington

INDUSTRY KEYWORDS:

The article Dendreon Announces Webcast Presentation at ROTH Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

(function(c,a){window.mixpanel=a;var b,d,h,e;b=c.createElement(“script”);
b.type=”text/javascript”;b.async=!0;b.src=(“https:”===c.location.protocol?”https:”:”http:”)+
‘//cdn.mxpnl.com/libs/mixpanel-2.2.min.js’;d=c.getElementsByTagName(“script”)[0];
d.parentNode.insertBefore(b,d);a._i=[];a.init=function(b,c,f){function d(a,b){
var c=b.split(“.”);2==c.length&&(a=a[c[0]],b=c[1]);a[b]=function(){a.push([b].concat(
Array.prototype.slice.call(arguments,0)))}}var g=a;”undefined”!==typeof f?g=a[f]=[]:
f=”mixpanel”;g.people=g.people||[];h=[‘disable’,’track’,’track_pageview’,’track_links’,
…read more
Source: FULL ARTICLE at DailyFinance